Back to today’s briefing

Story perspectives

AB Science Launches Major ALS Trial with Masitinib

1/29/2025

32 3

Summary

Story summary

AB Science is set to launch a pivotal Phase 3 trial, AB23005, to evaluate masitinib in ALS patients facing moderate disease. This new study, approved by the FDA and EMA, aims to enroll 408 participants, replacing the previous slow-recruiting trial. Over 48 weeks, researchers will closely monitor disease progression and the impact on patients' quality of life.

1 of 1

Story summary

AB Science is set to launch a pivotal Phase 3 trial, AB23005, to evaluate masitinib in ALS patients facing moderate disease. This new study, approved by the FDA and EMA, aims to enroll 408 participants, replacing the previous slow-recruiting trial. Over 48 weeks, researchers will closely monitor disease progression and the impact on patients' quality of life.